低剂量他莫昔芬在非浸润性乳腺肿瘤中的长期结果:个体参与者数据汇总分析
该研究汇总三项临床研究的1545例雌激素受体阳性或未知的导管原位癌、微浸润癌或高危乳腺病变女性,中位随访9.4年。绝经后女性获益显著(HR 0.51,95%CI 0.35-0.73),10年绝对风险降低11.2%;绝经前女性无显著减少(HR 0.90,95%CI 0.70-1.17),但对侧乳腺癌减少(HR 0.45,95%CI 0.26-0.76)。严重不良事件少见且组间相似。
要点
- 低剂量他莫昔芬在绝经后DCIS或高危病变女性中显著减少乳腺癌事件,10年绝对风险降低11.2%。
- 绝经前女性总体乳腺癌事件无显著减少,但对侧乳腺癌风险显著降低(HR 0.45)。
- 低剂量他莫昔芬严重不良事件少见且与对照组相似,支持剂量降阶梯以改善获益风险比。
核心结论
- 低剂量他莫昔芬与乳腺癌事件持续减少相关,且疗效因绝经状态和事件部位而异。
- 研究结果支持在内分泌预防治疗中采用剂量降阶梯策略,以改善DCIS和高危病变的获益风险比。
研究设计与样本
- 研究为三项临床研究的个体参与者数据汇总分析。
- 纳入1545例雌激素受体阳性或未知的DCIS、微浸润癌或高危乳腺病变女性,中位随访9.4年。
- 参与者接受低剂量他莫昔芬(5mg每日一次或10mg隔日一次,持续2-5年)或对照干预。
- 主要终点为无乳腺癌间期,定义为首次发生任何同侧或对侧浸润性乳腺癌、DCIS、区域复发或远处复发。
- 采用混合效应Cox模型估计风险比(HR),并考虑研究间变异。
主要发现
- 绝经后女性中,低剂量他莫昔芬组335例中发生40例乳腺癌事件,对照组401例中发生93例(HR 0.51,95%CI 0.35-0.73),10年绝对降低11.2%。
- 绝经前女性中未观察到乳腺癌事件的显著减少(HR 0.90,95%CI 0.70-1.17),但对侧乳腺癌减少(HR 0.45,95%CI 0.26-0.76)。
- 严重不良事件少见,且两组间相似。
关键数值与推荐
- 绝经后女性:低剂量他莫昔芬组乳腺癌事件40/335,对照组93/401,HR 0.51(95%CI 0.35-0.73),10年绝对降低11.2%。
- 绝经前女性:乳腺癌事件HR 0.90(95%CI 0.70-1.17),对侧乳腺癌HR 0.45(95%CI 0.26-0.76)。
临床怎么用
- 对于绝经后DCIS或高危乳腺病变女性,可考虑低剂量他莫昔芬以降低乳腺癌事件风险。
- 对于绝经前女性,低剂量他莫昔芬虽未显著减少总体乳腺癌事件,但可降低对侧乳腺癌风险,需个体化权衡。
- 低剂量他莫昔芬严重不良事件少见,支持在临床实践中采用剂量降阶梯策略改善获益风险比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tamoxifen 20 mg once-daily reduces the risk of breast cancer recurrence after ductal carcinoma in situ (DCIS), but its use is limited by adverse effects. Lower doses may be effective, but benefit durability and differences according to menopausal status and site of recurrence remain uncertain. METHODS: We conducted an individual-participant pooled analysis of three clinical studies involving women with estrogen receptor-positive or unknown DCIS, microinvasive carcinoma, or high-risk breast lesions. Participants received low-dose tamoxifen (5 mg once daily or 10 mg once-every other day for 2-5 years) or a control intervention. The primary end point was breast cancer-free interval, defined as the first occurrence of any ipsilateral or contralateral invasive breast cancer, DCIS, regional recurrence, or distant recurrence. Hazard ratios (HRs) were estimated with mixed-effects Cox models accounting for between-study variability. RESULTS: Among 1,545 women included with a median follow-up of 9.4 years, low-dose tamoxifen reduced breast cancer events overall, with evidence of treatment heterogeneity according to menopausal status (P = .01). In postmenopausal women, breast cancer events occurred in 40 of 335 receiving low-dose tamoxifen versus 93 of 401 controls (HR, 0.51 [95% CI, 0.35 to 0.73]), with a 10-year absolute reduction of 11.2%. Among premenopausal women, no significant reduction was observed (HR, 0.90 [95% CI, 0.70 to 1.17]), although contralateral breast cancer was reduced (HR, 0.45 [95% CI, 0.26 to 0.76]). Serious adverse events were infrequent and similar between groups. CONCLUSION: Low-dose tamoxifen was associated with a sustained reduction in breast cancer events, with differences by menopausal status and site of event. These findings support endocrine dose de-escalation to improve the benefit-risk profile of preventive therapy in DCIS and high-risk lesions.
引用
- Gandini S, Guerrieri-Gonzaga A, Serrano D, et al. Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis. J Clin Oncol. 2026. PMID: 42218652. doi:10.1200/JCO-26-00841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。